BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, January 8, 2026
See today's BioWorld Asia
Home
» It’s still early days for VC in China’s early stage biopharmas
To read the full story,
subscribe
or
sign in
.
It’s still early days for VC in China’s early stage biopharmas
March 26, 2014
By
Shannon Ellis
SHANGHAI – There are more bees than flowers in the China biopharma space, with venture capital (VC) interest outstripping the number of early stage companies with novel biologics to develop.
BioWorld Asia
